Arvinas (ARVN -29.7%) slumps on more than triple normal volume in reaction to updated data from a Phase 1/2 clinical trial evaluating ARV-110 in metastatic castration-resistant prostate cancer (mCRPC) patients.
20 patients were evaluable for prostate-specific antigen (PSA) response, including 12 patients treated at 140 mg or higher.
Seven of the 12 patients had forms of androgen
receptor (AR) degradable by ARV-110 (five did not). Of the seven, two
experienced PSA responses that have been sustained with additional
follow-up since the submission of the abstract, implying that five were
nonresponders.
On the safety front, a potential drug-drug
interaction between ARV-110 and resuvastatin (ROS) was observed. One
patient receiving 280 mg ARV-110 who was on ROS therapy experienced
life-threatening dose-limiting toxicity, elevated liver enzymes followed
by acute renal failure. A second resuvastatin patient who received 70
mg of ARV-110 experienced severe elevations in liver enzymes which
resolved after discontinuation of ROS.
Additional data should be available by year-end.
#ASCO20
https://seekingalpha.com/news/3578705-arvinas-down-30-on-underwhelming-arvminus-110-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.